Risk factors for rectal bleeding in prostate cancer after radiotherapy with a validation of current rectal dose constraints
DOI:
https://doi.org/10.2340/1651-226X.2025.42551Keywords:
rectal bleeding, curative radiotherapy, prostate cancerAbstract
Background: Rectal bleeding is a well-known adverse event following pelvic external beam radiotherapy (EBRT) for prostate cancer. This study investigates risk factors for rectal bleeding and validate our current rectal dose constraints in a real-world setting.
Material and methods: This prospective study includes 248 prostate cancer patients who received EBRT between 2017-2022. EBRT consisted of 56 Gy/39 fractions to the prostate, elective lymph nodes, and seminal vesicles with an integrated boost of 78 Gy to the prostate alone (≤T3a) or to the prostate and seminal vesicles (T3b). Rectal dose constraints were V50 Gy ≤50%, V70 Gy ≤20%, and V74 Gy ≤12%. Rectal bleeding was recorded at baseline and regularly duringfollow-up and included staff reported morbidity and patient reported outcome measures. Risk factors were evaluated in multivariate cox regression analysis.
Results: Median follow-up was 18 months (range 1-61 months). Sixteen percent (CI:11%;22%) of patients reported rectal bleeding as “rarely”, 4%(CI:2%;8%) “about half the time”, 0% “usually”, and 2%(CI:0%;4%) “always”. Five percent reported rectal bleeding as bothersome.
It was possible to comply with current rectal dose constraint (V74 Gy ≤12%) in 99.6% of all patients. Body mass index (BMI) (BMI:25-29.9, HR:0.54(CI:0.30;0.98), p=.044 or BMI>29.9, HR:0.40(CI:0.20;0.79), p=0.008)) were predictors for rectal bleeding.
Interpretation: Patient-reported rectal bleeding is common after prostate cancer radiotherapy. High BMI was a protective factor against rectal bleeding. No correlation was observed between rectal dose-volume constraints and the occurrence of rectal bleeding, suggesting that a rectal high-dose constraint of V74 Gy ≤12% is an adequate threshold to minimize patient-reported rectal bleeding.
Downloads
References
Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072–83.
https://doi.org/10.1016/j.ijrobp.2006.06.005 DOI: https://doi.org/10.1016/j.ijrobp.2006.06.005
Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, et al. Functional outcomes after localized prostate cancer treatment. JAMA. 2024;331(4):302–17.
https://doi.org/10.1001/jama.2023.26491 DOI: https://doi.org/10.1001/jama.2023.26491
Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, et al. Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys. 2013;86(3):546–53.
https://doi.org/10.1016/j.ijrobp.2013.01.036 DOI: https://doi.org/10.1016/j.ijrobp.2013.01.036
Massi MC, Gasperoni F, Ieva F, Paganoni AM, Zunino P, Manzoni A, et al. A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE multi-national cohort. Front Oncol. 2020;10:541281.
https://doi.org/10.3389/fonc.2020.541281 DOI: https://doi.org/10.3389/fonc.2020.541281
Bae BK, Kim JE, Pyo H, Hong SN, Park W. Long-term findings of rectal endoscopy and rectal bleeding after moderately hypofractionated, intensity-modulated radiotherapy for prostate cancer. Sci Rep. 2023;13(1):22099.
https://doi.org/10.1038/s41598-023-43202-x DOI: https://doi.org/10.1038/s41598-023-43202-x
Matzinger O, Duclos F, van den Bergh A, Carrie C, Villà S, Kitsios P, et al. Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. Eur J Cancer. 2009;45(16):2825–34.
https://doi.org/10.1016/j.ejca.2009.07.009 DOI: https://doi.org/10.1016/j.ejca.2009.07.009
Choe KS, Jani AB, Liauw SL. External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity? Int J Radiat Oncol Biol Phys. 2010;76(3):755–60.
https://doi.org/10.1016/j.ijrobp.2009.02.026 DOI: https://doi.org/10.1016/j.ijrobp.2009.02.026
Otsuka K, Otsuka M, Itaya T, Matsumoto A, Sato R, Sagara Y, et al. Risk factors for rectal bleeding after volumetric-modulated arc radiotherapy of prostate cancer. Rep Pract Oncol Radiother. 2023;28(1):15–23.
https://doi.org/10.5603/RPOR.a2023.0010 DOI: https://doi.org/10.5603/RPOR.a2023.0010
Someya M, Hori M, Tateoka K, Nakata K, Takagi M, Saito M, et al. Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. J Radiat Res. 2015;56(1):122–7.
https://doi.org/10.1093/jrr/rru080 DOI: https://doi.org/10.1093/jrr/rru080
Movsas B, Rodgers JP, Elshaikh MA, Martinez AA, Morton GC, Krauss DJ, et al. Dose-escalated radiation alone or in combination with short-term total androgen suppression for intermediate-risk prostate cancer: patient-reported outcomes from NRG/Radiation Therapy Oncology Group 0815 randomized trial. J Clin Oncol. 2023;41(17):3217–24.
https://doi.org/10.1200/jco.22.02389 DOI: https://doi.org/10.1200/JCO.22.02389
Krol R, Smeenk RJ, van Lin EN, Yeoh EE, Hopman WP. Systematic review: anal and rectal changes after radiotherapy for prostate cancer. Int J Colorectal Dis. 2014;29(3):273–83.
https://doi.org/10.1007/s00384-013-1784-8 DOI: https://doi.org/10.1007/s00384-013-1784-8
Tucker SL, Michalski JM, Bosch WR, Mohan R, Dong L, Winter K, et al. Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. Radiother Oncol. 2012;104(1):109–13.
https://doi.org/10.1016/j.radonc.2012.04.023 DOI: https://doi.org/10.1016/j.radonc.2012.04.023
Kotabe K, Nakayama H, Takashi A, Takahashi A, Tajima T, Kume H. Association between rectal bleeding and the absolute dose volume of the rectum following image-guided radiotherapy for patients with prostate cancer. Oncol Lett. 2018;16(2):2741–9.
https://doi.org/10.3892/ol.2018.8888 DOI: https://doi.org/10.3892/ol.2018.8888
Tucker SL, Dong L, Michalski JM, Bosch WR, Winter K, Cox JD, et al. Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. Int J Radiat Oncol Biol Phys. 2012;84(2):390–5.
https://doi.org/10.1016/j.ijrobp.2011.11.073 DOI: https://doi.org/10.1016/j.ijrobp.2011.11.073
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.
https://doi.org/10.1016/0360-3016(95)00060-c DOI: https://doi.org/10.1016/0360-3016(95)00060-C
Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57(4):953–62.
https://doi.org/10.1016/s0360-3016(03)00665-5 DOI: https://doi.org/10.1016/S0360-3016(03)00665-5
D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–74.
https://doi.org/10.1001/jama.280.11.969 DOI: https://doi.org/10.1001/jama.280.11.969
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.
https://doi.org/10.1016/j.eururo.2020.09.042 DOI: https://doi.org/10.1016/j.eururo.2020.09.042
Nitsche M, Brannath W, Brückner M, Wagner D, Kaltenborn A, Temme N, et al. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use? Br J Radiol. 2017;90(1070):20160370.
https://doi.org/10.1259/bjr.20160370 DOI: https://doi.org/10.1259/bjr.20160370
Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186(3):865–72.
https://doi.org/10.1016/j.juro.2011.04.085 DOI: https://doi.org/10.1016/j.juro.2011.04.085
Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. 2010 [updated June 14, 2010; cited 2022 Nov 15]. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Šegedin B, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016;120(3):412–9.
https://doi.org/10.1016/j.radonc.2016.06.006 DOI: https://doi.org/10.1016/j.radonc.2016.06.006
Fellin G, Fiorino C, Rancati T, Vavassori V, Baccolini M, Bianchi C, et al. Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol. 2009;93(2):197–202.
https://doi.org/10.1016/j.radonc.2009.09.004 DOI: https://doi.org/10.1016/j.radonc.2009.09.004
Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, et al. Multinational prospective study of patient-reported outcomes after prostate radiation therapy: detailed assessment of rectal bleeding. Int J Radiat Oncol Biol Phys. 2016;96(4):770–7.
https://doi.org/10.1016/j.ijrobp.2016.07.038 DOI: https://doi.org/10.1016/j.ijrobp.2016.07.038
King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877–82.
https://doi.org/10.1016/j.ijrobp.2010.11.054 DOI: https://doi.org/10.1016/j.ijrobp.2010.11.054
Pinkawa M, Gharib A, Schlenter M, Timm L, Eble MJ. Quality of life more than 10 years after radiotherapy for localized prostate cancer-impact of time after treatment and prescription dose. Qual Life Res. 2021;30(2):437–43.
https://doi.org/10.1007/s11136-020-02639-7 DOI: https://doi.org/10.1007/s11136-020-02639-7
Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669–76.
https://doi.org/10.1007/s00520-016-3297-9 DOI: https://doi.org/10.1007/s00520-016-3297-9
Jensen NBK, Pötter R, Kirchheiner K, Fokdal L, Lindegaard JC, Kirisits C, et al. Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: physician- and patient reported outcome from the EMBRACE study. Radiother Oncol. 2018;127(3):431–9.
https://doi.org/10.1016/j.radonc.2018.05.016 DOI: https://doi.org/10.1016/j.radonc.2018.05.016
Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, et al. Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):83–9.
https://doi.org/10.1016/j.ijrobp.2007.05.051 DOI: https://doi.org/10.1016/j.ijrobp.2007.05.051
Thomas RJ, Holm M, Williams M, Bowman E, Bellamy P, Andreyev J, et al. Lifestyle factors correlate with the risk of late pelvic symptoms after prostatic radiotherapy. Clin Oncol (R Coll Radiol). 2013;25(4):246–51.
https://doi.org/10.1016/j.clon.2012.11.007 DOI: https://doi.org/10.1016/j.clon.2012.11.007
Koneru H, Cyr R, Feng LR, Bae E, Danner MT, Ayoob M, et al. The impact of obesity on patient reported outcomes following stereotactic body radiation therapy for prostate cancer. Cureus. 2016;8(7):e669.
https://doi.org/10.7759/cureus.669 DOI: https://doi.org/10.7759/cureus.669
Gulliford SL, Ghose S, Ebert MA, Kennedy A, Dowling J, Mitra J, et al. Radiotherapy dose-distribution to the perirectal fat space (PRS) is related to gastrointestinal control-related complications. Clin Transl Radiat Oncol. 2017;7:62–70.
https://doi.org/10.1016/j.ctro.2017.10.002 DOI: https://doi.org/10.1016/j.ctro.2017.10.002
Takeda K, Ogawa Y, Ariga H, Koto M, Sakayauchi T, Fujimoto K, et al. Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer. Anticancer Res. 2009;29(5):1831–4.
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.
https://doi.org/10.1016/S1470-2045(16)30102-4 DOI: https://doi.org/10.1016/S1470-2045(16)30102-4
Roach M, Chung H, Hsu I, Morton G, Gomella L, Wallace R, et al. Radiation Therapy Oncology Group RTOG 0924, Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial. Protocol. 2018. https://www.nrgoncology.org/Clinical-Trials/Protocol/rtog-0924?filter=rtog-0924
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Ellen Lund Schaldemose, Christine Vestergaard Madsen, Ahmed Hussein Zedan, Martin Berg, Henrik Dahl Nissen, Terje Andersen, Bjarke Mortensen , Lars Ulrik Fokdal
This work is licensed under a Creative Commons Attribution 4.0 International License.
